JP2017508467A - がんを処置するためのｒｎａを含む医薬組成物および使用 - Google Patents

がんを処置するためのｒｎａを含む医薬組成物および使用 Download PDF

Info

Publication number
JP2017508467A
JP2017508467A JP2016555990A JP2016555990A JP2017508467A JP 2017508467 A JP2017508467 A JP 2017508467A JP 2016555990 A JP2016555990 A JP 2016555990A JP 2016555990 A JP2016555990 A JP 2016555990A JP 2017508467 A JP2017508467 A JP 2017508467A
Authority
JP
Japan
Prior art keywords
seq
rna molecule
rnase
sequence
coding chimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016555990A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017508467A5 (enExample
Inventor
エリス， ルイス オー． ブルヅィオ
エリス， ルイス オー． ブルヅィオ
メネンデス， ヴェロニカ エー． ブルヅィオ
メネンデス， ヴェロニカ エー． ブルヅィオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Andes Biotechnologies SA
Original Assignee
Andes Biotechnologies SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andes Biotechnologies SA filed Critical Andes Biotechnologies SA
Publication of JP2017508467A publication Critical patent/JP2017508467A/ja
Publication of JP2017508467A5 publication Critical patent/JP2017508467A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C12N2330/31—Libraries, arrays

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016555990A 2014-03-14 2015-03-13 がんを処置するためのｒｎａを含む医薬組成物および使用 Withdrawn JP2017508467A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461953672P 2014-03-14 2014-03-14
US61/953,672 2014-03-14
PCT/IB2015/001233 WO2015150924A2 (en) 2014-03-14 2015-03-13 Pharmaceutical compositions comprising rna and use for treating cancer

Publications (2)

Publication Number Publication Date
JP2017508467A true JP2017508467A (ja) 2017-03-30
JP2017508467A5 JP2017508467A5 (enExample) 2018-04-19

Family

ID=54241387

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016555990A Withdrawn JP2017508467A (ja) 2014-03-14 2015-03-13 がんを処置するためのｒｎａを含む医薬組成物および使用

Country Status (5)

Country Link
US (1) US20170183650A1 (enExample)
EP (1) EP3116513A4 (enExample)
JP (1) JP2017508467A (enExample)
CA (1) CA2939860A1 (enExample)
WO (1) WO2015150924A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111603477B (zh) * 2019-02-25 2023-06-02 中国科学院分子细胞科学卓越创新中心 环形rna在系统性红斑狼疮制备治疗药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2406169B (en) * 2002-06-12 2006-11-01 Ambion Inc Methods and compositions relating to labeled rna molecules that reduce gene expression
US6975830B2 (en) * 2002-09-12 2005-12-13 Ricoh Company, Limited Image forming apparatus, process cartridge, and waste toner recovery device
EP2270159B1 (en) * 2003-05-21 2015-01-07 Andes Biotechnologies S.A. Markers for pre-cancer and cancer cells and the method to interfere with cell proliferation therein
CA2647338A1 (en) * 2006-04-28 2007-11-08 Avexa Limited Integrase inhibitors-3
DE102008040682A1 (de) * 2008-07-24 2010-01-28 Robert Bosch Gmbh Sensoranordnung und Verfahren zum Betrieb einer Sensoranordnung
WO2012103154A1 (en) * 2011-01-24 2012-08-02 Nugen Technologies, Inc. Stem-loop composite rna-dna adaptor-primers: compositions and methods for library generation, amplification and other downstream manipulations

Also Published As

Publication number Publication date
EP3116513A4 (en) 2017-10-25
CA2939860A1 (en) 2015-10-08
WO2015150924A2 (en) 2015-10-08
WO2015150924A3 (en) 2016-06-09
US20170183650A1 (en) 2017-06-29
EP3116513A2 (en) 2017-01-18

Similar Documents

Publication Publication Date Title
US10767178B2 (en) Compositions and methods of using piRNAS in cancer diagnostics and therapeutics
JP2015518714A (ja) 遺伝子発現を調節するための組成物及び方法
KR20180098528A (ko) 유전자 발현의 조절 및 탈조절된 단백질 발현의 스크리닝
TW200812590A (en) Methods for cancer therapy and stem cell modulation
TW200800236A (en) Sensitizing a cell to cancer treatment by modulating the activity of a nucleic acid encoding RPS27L protein
US11845938B2 (en) Aptamer compositions and the use thereof
KR101142080B1 (ko) 전립선암 및 다른 암의 치료 방법 및 조성물
JP2017533728A (ja) トランスフェリン受容体（ｔｆｒ）に対するｒｎａアプタマー
JP2022031642A (ja) アンチセンスオリゴヌクレオチド
Maleki et al. Multiple interactions between melatonin and non‐coding RNAs in cancer biology
JP2024054419A (ja) 新規のコンジュゲートされた核酸分子及びその使用
KR20200068647A (ko) 트랜스페린 수용체 (TfR)에 대한 RNA 앱타머
JP2024503711A (ja) 修飾ｍｉＲ－１３５、そのコンジュゲートおよびその使用
Liu et al. Enhancement of cisplatin cytotoxicity by Retigeric acid B involves blocking DNA repair and activating DR5 in prostate cancer cells
TW201625273A (zh) 細胞凋亡誘導劑
EP2970970A1 (en) Antisense oligonucleotides for treatment of cancer stem cells
Weerasinghe et al. T40214/PEI complex: a potent therapeutics for prostate cancer that targets STAT3 signaling
JP2022506958A (ja) Ｍｉｒ－１０ｂ活性を調節するためのマイクロｒｎａ化合物及び方法
US9228189B2 (en) C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
JP2017508467A (ja) がんを処置するためのｒｎａを含む医薬組成物および使用
CA2887702C (en) C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
US7528117B2 (en) High efficacy antisense RIαPKA poly-DNP oligoribonucleotides
JP2024539435A (ja) がんの免疫療法的治療のためのｃＧＡＳ－ＳＴＩＮＧ及びＳＴＡＴ３経路変調のための球状核酸
CN117440816A (zh) 修饰的mir-135、其缀合形式及其用途
CN107106697A (zh) Pdgfr rna适体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161115

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20180112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180312

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180312

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20181130